Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioventus Inc. stock logo
BVS
Bioventus
$7.29
+18.7%
$6.65
$5.81
$14.38
$598.83M0.83392,697 shs1.20 million shs
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$3.82
-2.6%
$3.62
$1.60
$16.55
$283.55M1.17958,910 shs673,499 shs
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$7.17
+18.1%
$6.01
$4.61
$9.97
$150.69M1.81152,730 shs297,680 shs
K2M Group Holdings, Inc. stock logo
KTWO
K2M Group
$27.50
$0.00
$16.44
$27.50
$1.20B1.431.85 million shsN/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioventus Inc. stock logo
BVS
Bioventus
+18.73%+11.47%+6.89%+7.44%-9.89%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-2.55%-1.55%+9.77%+57.85%-69.12%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
+18.12%+25.57%+14.72%+31.08%+3.91%
K2M Group Holdings, Inc. stock logo
KTWO
K2M Group
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioventus Inc. stock logo
BVS
Bioventus
2.9074 of 5 stars
3.40.00.00.01.73.31.3
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
2.5015 of 5 stars
4.61.00.00.02.60.80.0
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
2.8369 of 5 stars
2.03.00.00.02.44.21.9
K2M Group Holdings, Inc. stock logo
KTWO
K2M Group
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioventus Inc. stock logo
BVS
Bioventus
2.75
Moderate Buy$13.7588.61% Upside
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.56228.68% Upside
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
4.00
Strong Buy$12.5074.34% Upside
K2M Group Holdings, Inc. stock logo
KTWO
K2M Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest KTWO, BVS, CATX, and INFU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
7/21/2025
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/12/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/7/2025
Bioventus Inc. stock logo
BVS
Bioventus
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$12.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $12.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00
6/3/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00
5/14/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
5/13/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
5/8/2025
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/7/2025
Bioventus Inc. stock logo
BVS
Bioventus
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$15.00
(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioventus Inc. stock logo
BVS
Bioventus
$567.70M1.05$0.58 per share12.58$2.80 per share2.60
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/A$2.67 per shareN/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$137.58M1.10$0.56 per share12.79$2.47 per share2.90
K2M Group Holdings, Inc. stock logo
KTWO
K2M Group
$258.03M4.66N/AN/A$5.59 per share4.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioventus Inc. stock logo
BVS
Bioventus
-$156.23M-$0.48N/A15.85N/A-7.11%15.61%4.01%N/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/13/2025 (Estimated)
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$870K$0.14119.5223.13N/A1.12%2.78%1.41%N/A
K2M Group Holdings, Inc. stock logo
KTWO
K2M Group
-$37.14M-$0.87N/AN/AN/A-16.66%-19.69%-11.71%N/A

Latest KTWO, BVS, CATX, and INFU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025N/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$0.30N/AN/AN/A$0.17 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
N/AN/AN/AN/AN/A
K2M Group Holdings, Inc. stock logo
KTWO
K2M Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioventus Inc. stock logo
BVS
Bioventus
1.85
1.41
0.99
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
9.60
9.60
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
0.50
1.98
1.59
K2M Group Holdings, Inc. stock logo
KTWO
K2M Group
0.55
3.10
1.79

Institutional Ownership

CompanyInstitutional Ownership
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
71.13%
K2M Group Holdings, Inc. stock logo
KTWO
K2M Group
N/A

Insider Ownership

CompanyInsider Ownership
Bioventus Inc. stock logo
BVS
Bioventus
33.00%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.72%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
11.40%
K2M Group Holdings, Inc. stock logo
KTWO
K2M Group
6.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioventus Inc. stock logo
BVS
Bioventus
1,20082.14 million54.46 millionNot Optionable
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.23 million65.21 millionOptionable
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
41021.02 million19.10 millionOptionable
K2M Group Holdings, Inc. stock logo
KTWO
K2M Group
N/A43.74 millionN/AOptionable

Recent News About These Companies

Alternergy taps K2M of Denmark to develop 164-MW wind projects
Jiani Navarro
Carmine Gemei
K2M Group Holdings Inc (KTWO)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bioventus stock logo

Bioventus NYSE:BVS

$7.29 +1.15 (+18.73%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$7.25 -0.04 (-0.55%)
As of 08/6/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Perspective Therapeutics stock logo

Perspective Therapeutics NYSE:CATX

$3.82 -0.10 (-2.55%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$3.75 -0.07 (-1.83%)
As of 08/6/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

InfuSystem stock logo

InfuSystem NYSE:INFU

$7.17 +1.10 (+18.12%)
Closing price 08/6/2025 04:00 PM Eastern
Extended Trading
$7.18 +0.01 (+0.21%)
As of 08/6/2025 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

K2M Group stock logo

K2M Group NASDAQ:KTWO

K2M Group Holdings, Inc., a medical device company, provides spine and minimally invasive solutions in the United States and internationally. The company offers implants, disposables, and instruments primarily to hospitals for use by spine surgeons to treat spinal pathologies, such as deformity, trauma, and tumor. Its complex spine products include EVEREST, MESA, and MESA 2 deformity spinal systems; NILE alternative and proximal fixation spinal systems; MESA rail deformity spinal systems; Cricket spinal correction rod reduction instrumentation; CAPRI corpectomy cage systems; MESA small stature, rail small stature, and mini spinal systems; SERENGETI complex spine minimally invasive retractor systems; RAVINE complex spine lateral access systems; SANTORINI corpectomy cage systems; YUKON OCT spinal systems; and PALO ALTO cervical static corpectomy cage systems. The company's minimally invasive surgery products consist of EVEREST minimally invasive spinal and XT spinal, SERENGETI minimally invasive retractor, MOJAVE PL 3D expandable interbody, RAVINE lateral access, CASCADIA lateral 3D interbody, ALEUTIAN lateral interbody, and TERRA NOVA minimally invasive access systems. In addition, its degenerative spine products comprise EVEREST degenerative spinal, CASCADIA and ALEUTIAN interbody, SAHARA AL expandable stabilization, RHINE cervical disc, CHESAPEAKE interbody, PYRENEES cervical plate, and BLUE RIDGE hybrid cervical plate systems. Further, the company provides Balance ACS, a platform that includes tools to assist surgeons with obtaining authorization from healthcare insurers. K2M Group Holdings, Inc. markets and sells its products through direct sales employees, independent sales agencies, and distributor partners. The company was founded in 2004 and is headquartered in Leesburg, Virginia.